Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fresubin protein energy Drink is a high-protein, high-energy oral nutritional supplement (sip feed) manufactured by Fresenius Kabi. It is a nutritionally complete, hypercaloric liquid formulation providing 1.5 kcal/ml, with an energy distribution of approximately 27% protein, 40% fat, and 33% carbohydrate. The primary active ingredients include milk proteins (caseinate and whey protein), vegetable oils (rapeseed and sunflower oil), and carbohydrates (maltodextrin and sucrose), supplemented with a full range of vitamins, minerals, and trace elements. Classified as a Food for Special Medical Purposes (FSMP), it is indicated for the dietary management of patients with or at risk of disease-related malnutrition, particularly those with increased protein and energy needs. This includes patients with cancer, COPD, heart failure, inflammatory bowel disease, or those undergoing hemodialysis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fresubin protein energy Drink.